Latest research on Olmesartan medoxomil

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Olmesartan medoxomil indications

Therefore, we hypothesized that Olmesartan medoxomil may also reduce EAT volume, finally achieving an anti-atherosclerosis effect. [source, 2016]
The purpose of this study is to verify that Olmesartan medoxomil is effective in the treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. [source, 2016]
The novelty of this study is that we intend to explore the effect of Olmesartan medoxomil on both plaque volume and epicardial fat. [source, 2016]
This study will accomplish two goals: (1) it will explain the relationship between EAT volume and coronary atherosclerosis progression and (2) it will verify the effect of Olmesartan medoxomil on EAT volume reduction and coronary atherosclerosis progression. [source, 2016]
Evidence that Olmesartan medoxomil is effective on EAT volume reduction and coronary atherosclerosis progression would be very attractive to clinicians and patients. [source, 2016]
Olmesartan medoxomil also proved to be effective in controlling blood pressure, regardless of the type of hypertension. [source, 2015]
In a sub-analysis of the TRINITY trial (Triple therapy with Olmesartan medoxomil, Amlodipine, and Hydrochlorothiazide in hypertensive patients; number, NCT00649389) the effect of triple combination therapy was assessed, with doses up to 40 mg of olmesartan, 10 mg of Amlodipine, and 25 mg of Hydrochlorothiazide, using ABPM in 440 patients with HTN defined as moderate to severe based on a systolic BP ≥160 mmHg or a diastolic BP ≥100 mmHg. [source, 2015]
Here, we investigated the effects of the AT1 receptor blocker Olmesartan medoxomil and the calcium channel antagonist Amlodipine besylate on atherosclerotic progression and vascular inflammation using an ApoE−/− mouse model of advanced atherosclerosis. [source, 2015]
Treatment with the combination of Olmesartan medoxomil and Amlodipine besylate showed no significant effect on lesion composition. [source, 2015]
There was a trend to a more intense downregulation of NF-κB in the combined treatment group compared to monotherapy with Olmesartan medoxomil or Amlodipine besylate, but this effect did not reach significance (Figure 4). [source, 2015]